| 臺大學術典藏 |
2022-03-04T06:55:01Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
SIH-HAN LIAO; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:41Z |
Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma.
|
Liang J.D.; Yang P.M.; Huang G.T.; Lee H.S.; CHIEN-HUNG CHEN; Liang P.C.; Sheu J.C.; Chen D.S. |
| 臺大學術典藏 |
2022-02-23T02:12:28Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:27Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment
|
Chang P.-Y.; Huang C.-C.; Hung C.-H.; Yu C.-Y.; Wu D.-K.; Hwang J.-I.; Liang P.-C.; Wu R.-H.; Tsai W.-L.; Lin Y.-J.; Liu Y.-S.; Liang H.-L.; Lee R.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:23Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; CHIEN-HUNG CHEN; Kao J.-H. |
| 臺大學術典藏 |
2022-02-23T02:12:20Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:36Z |
Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma.
|
Liang J.D.; Yang P.M.; Huang G.T.; Lee H.S.; CHIEN-HUNG CHEN; Liang P.C.; Sheu J.C.; Chen D.S. |
| 臺大學術典藏 |
2022-02-22T05:34:20Z |
Tumor lysis syndrome after transarterial chemoembolization plus portal venous embolization for hepatocellular carcinoma
|
Tsai W.-L.; Liang P.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:18Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:14Z |
Multidisciplinary Taiwan consensus recommendations for the use of DEBDOX-TACE in hepatocellular carcinoma treatment
|
Chang P.-Y.; Huang C.-C.; Hung C.-H.; Yu C.-Y.; Wu D.-K.; Hwang J.-I.; Liang P.-C.; Wu R.-H.; Tsai W.-L.; Lin Y.-J.; Liu Y.-S.; Liang H.-L.; Lee R.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:13Z |
Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma
|
Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; CHIEN-HUNG CHEN; Kao J.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:57Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; YU-YUN SHAO; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:56Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:55Z |
Revisiting hepatic artery infusion chemotherapy in the treatment of advanced hepatocellular carcinoma
|
Chen C.-T.; Liu T.-H.; YU-YUN SHAO; Liu K.-L.; Liang P.-C.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-16T03:00:55Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao, Yu-Yun; Wang, Shen-Yung; Lin, Shi-Ming; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; JA-DER LIANG |
| 臺大學術典藏 |
2022-02-07T03:29:04Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-07T03:29:03Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-01-25T05:10:42Z |
Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis
|
Chang M.-C.; Chang Y.-T.; Su T.-C.; Yang W.-S.; CHI-LING CHEN; Tien Y.-W.; Liang P.-C.; Wei S.-C.; Wong J.-M. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
